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Abstract
Genome-wide association studies (GWAS) have repeatedly shown an association between non-coding variants in the TCF7L2
locus and risk for type 2 diabetes (T2D), implicating a role for cis-regulatory variation within this locus in disease etiology.
Supporting this hypothesis, we previously localized complex regulatory activity to the TCF7L2 T2D-associated interval using
an in vivo bacterial artificial chromosome (BAC) enhancer-trapping reporter strategy. To follow-up on this broad initial
survey of the TCF7L2 regulatory landscape, we performed a fine-mapping enhancer scan using in vivo mouse transgenic
reporter assays. We functionally interrogated approximately 50% of the sequences within the T2D-associated interval,
utilizing sequence conservation within this 92-kb interval to determine the regulatory potential of all evolutionary
conserved sequences that exhibited conservation to the non-eutherian mammal opossum. Included in this study was a
detailed functional interrogation of sequences spanning both protective and risk alleles of single nucleotide polymorphism
(SNP) rs7903146, which has exhibited allele-specific enhancer function in pancreatic beta cells. Using these assays, we
identified nine segments regulating various aspects of the TCF7L2 expression profile and that constitute nearly 70% of the
sequences tested. These results highlight the regulatory complexity of this interval and support the notion that a TCF7L2 cis-
regulatory disruption leads to T2D predisposition.
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Introduction
Intronic variation located in a 92-kb interval within the
Transcription Factor 7-Like 2 (TCF7L2) gene locus, a transcriptional
regulator of canonical Wnt signaling [1,2], is the strongest
determinant for type 2 diabetes (T2D) susceptibility identified to
date [3,4,5]. Indeed, associations have been reported in popula-
tions from across the globe [4] and variation in this locus remain
the strongest genetic determinant of T2D risk in humans [6]. As
both in vitro and in vivo functional analyses support a role for
TCF7L2 in glucose metabolism [7,8,9,10,11,12,13,14,15], this
transcription factor is regarded as the candidate target gene of the
association.
The underlying molecular, cellular and physiological mecha-
nism(s) by which TCF7L2 affects T2D risk are largely unknown.
The results, to date, point to a role for variation in long-range cis-
regulatory elements in T2D pathogenesis through alterations in
TCF7L2 expression. In this regard, two independent studies in
pancreatic islets uncovered allele-specific enhancer activity for
sequences spanning single nucleotide polymorphism (SNP)
rs7903146, the variant showing the strongest association to
T2D [16,17]. These analyses are consistent with the recent
functional studies of non-coding variants in other disease-
associated GWAS loci and highlight the importance of cis-
regulatory variation in affecting disease risk [18]. From the
standpoint of the common disease common variant (CDCV)
hypothesis, the implications for common disease risk are clear as
variation in these regulatory sequences can lead to a compart-
mentalization of phenotypic effects as enhancer elements largely
govern activity in a spatial and temporal context, mitigating
pleiotropic effects [18]. This would ostensibly allow these
disadvantageous non-coding variants to reach higher frequencies
in human populations as compared with protein-coding variants
that can elicit disruptions with broader consequences on target
gene activity [18].
We previously interrogated the cis-regulatory landscape of
TCF7L2 using a bacterial artificial chromosome (BAC) enhancer-
trapping strategy and identified widespread enhancer activity that
we localized to the association interval [12]. However, a systematic
fine-mapping analysis of the association interval is still lacking. To
follow-up on this BAC survey, here we characterized the long-
range cis-regulatory landscape of this T2D-associated genomic
locus through an in vivo fine-mapping approach. We demonstrate
that the association interval harbors a wide variety of tissue-
specific enhancers, including a subset that drives expression in
peripheral tissues involved in glucose homeostasis, adding support
to a potential regulatory defect in T2D etiology.
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Ethics Statement
All mice were housed at the University of Chicago. Veterinary
care was available on a 24-hour basis. Mice were monitored daily
for any signs of illness or discomfort. All experiments were
conducted in strict accordance with institutional rules and
approved by the University of Chicago Institutional Animal Care
and Use Committee, protocol number 71656 (M.A.N.).
Molecular cloning
Conserved sequences within the association interval were
cloned (Table S1) with Gateway technology (Invitrogen) in a
custom vector containing a heat shock minimal promoter (Hsp68)
driving lacZ expression. The transgenic lacZ plasmids were
linearized, resuspended in 1x microinjection buffer and used for
pronuclear injection into fertilized oocytes (CD-1) using standard
protocols approved by the University of Chicago Institutional
Animal Care and Use Committee.
Mouse in vivo Transgenic Reporter Assays
Animals were sacrificed using carbon dioxide gas followed by
cervical dislocation. Embryos were harvested at embryonic
day 15.5 (E15.5) or 16.5 (E16.5). Pancreatic staining was also
performed postnatally on day 0 (P0) and 6 (P6). Following
harvesting and dissection, embryos and tissues were placed into
cold 100 mM phosphate buffer, pH 7.3 (PBS), followed by an
hour of incubation with 4% paraformaldehyde at 4uC. Tissues
were then washed with 1x PBS and further washed two additional
times for 20 min using lacZ wash buffer (2 mM MgCl2; 0.01%
deoxycholate; 0.02% NP-40; 100 mM phosphate buffer, pH 7.3),
and stained for 16–20 hours at room temperature with lacZ
staining solution (1 mg/ml X-gal; 4 mM potassium ferrocyanide;
4 mM potassium ferricyanide; 20 mM Tris-HCl, pH 7.5 in wash
buffer). After staining, embryos and tissues were rinsed 5 times in
PBS and post-fixed and stored in 4% paraformaldehyde at 4uC.
Images were taken using a Leica MZ 16 F imaging system.
Results
Enhancer fine-mapping at the TCF7L2 association interval
As sequence conservation is a predictor of function [19], 13
evolutionary conserved regions (ECRs) spanning sequences
exhibiting significant conservation between human and the non-
eutherian mammal opossum were tested in mouse transgenic
assays (Figure 1). These ECRs were cloned into a lacZ reporter
construct driven by a heat shock protein 68 (Hsp68) minimal
promoter. In total ,48.7 kb of sequence, or approximately 50%
of the T2D-associated interval, was tested for regulatory activity in
vivo (Figure 1A). For each construct, we obtained multiple
transgenic lines to ensure reproducibility of enhancer patterns
across independent transgenic lines. Of the 13 evolutionarily
conserved regions, we observed reproducible enhancer activity in
9/13 (69%) regions tested (ECR 1, 3, 4, 5, 6, 8, 9, 11 and 13).
The enhancers mapping to these intervals exhibit a diverse
array of spatial expression patterns that were reproducible across
independent transgenic lines (Figure 1B). Interestingly, five regions
(ECR 1, 4, 5, 11 and 13) exhibited regulatory potential in tissues
with known roles in controlling glucose homeostasis such as the
stomach (ECR 1), bone (ECR 4 and 13) and brain (ECR 5 and
11). Beta-galactosidase staining was also localized to spinal
neurons (ECR 3), walking pads (ECR 6) and the vasculature of
both the limbs (ECR 8) and brain (ECR 9).
Functional analysis of sequences spanning SNP
rs7903146
We next investigated the regulatory potential of sequences
containing SNP rs7903146. For this analysis, we utilized the
previous results of the construct that encompassed the protective C
allele at SNP rs7903146 from ECR 5 (ECR 5-C) and engineered
an identical construct that spanned the risk T allele at SNP
rs7903146 (ECR 5-T; Figure 2A). In order to dissociate any
regulatory effects exhibited by a conserved sequence situated
downstream of this SNP, we further generated a shorter construct
(ECR 5B) that was restricted to this region of conservation
(Figure 2A). As SNP rs7903146 resides within a primate-specific
short interspersed nuclear element (SINE) and ‘enhancer boosting’
properties were demonstrated for repetitive elements [20], this
approach also allows for the identification of potential ‘enhancer
boosting’ activity. All constructs were sequence-verified prior to
pronuclei injections. For each of these new constructs, we obtained
multiple transgenic lines (Figure 2B, C, D).
All constructs exhibited reproducible expression within the
forebrain across multiple transgenic lines, suggesting that the
conserved sequence downstream of SNP rs7903146 governs this
activity (Figure 2B, C, D). However, we observed no allelic-specific
(comparing ECR 5-C and 5-T) or ‘enhancer boosting’ effects
(comparing ECR 5B and 5-C/T) as forebrain expression across all
constructs was largely consistent. Although some pancreatic
expression was present in mice harboring the longer constructs
encompassing SNP rs7903146 (ECR 5-C and 5-T) and this
pattern was absent in transgenic lines containing the shorter
construct ECR 5B, this activity was not highly reproducible across
multiple independent transgenic lines, nor did this expression
exhibit allelic-specific effects. This conclusion is further corrobo-
rated by analyses at postnatal developmental stages in transgenic
animals as consistent allelic differences were not observed at
postnatal days 0 or 6 (Figure S1).
Discussion
Our screen defines the fine-scale regulatory landscape of the
TCF7L2 T2D-associated region. To our knowledge, this is the first
detailed mapping study conducted on this GWAS-associated
region. Importantly, the enhancers identified from this fine-
mapping scan recapitulate various aspects of BAC enhancer
activities that we previously uncovered at this locus [12]. While
significant attention has been given to the role of TCF7L2 in
pancreatic islets, our data delineates several regions harboring
regulator activity in peripheral metabolic tissues. In particular, we
identified elements that govern expression within the bone, brain
and stomach.
The localization of bone enhancers is not surprising, given the
well established role of the canonical Wnt signaling in bone
formation [21]. For instance, ablation of Wnt regulators leads to
bone mass defects in mice [22,23,24,25] while disruptions of Wnt
signaling antagonists generates opposing phenotypes [26,27]. As a
previously unappreciated role for bone in the regulation of glucose
homeostasis has been recently established, this organ has become
an interest to the diabetes community [28,29]. Consequently,
investigations of this transcription factor in bone-mediated glucose
metabolism are clearly warranted.
The fine-mapping of a stomach enhancer within the associated
interval is of relevance as this tissue secretes the orexigenic
hormone ghrelin that is involved in energy and glucose
homeostasis [30,31]. A recent study further uncovered a correla-
tion between a putative TCF7L2 neuroendocrine splicing variant
and the anorexigenic peptide CART [32], supporting a role for this
Tissue-Specific Enhancers in a Diabetes GWAS Locus
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36501canonical Wnt regulator in satiety. The extent of TCF7L2
involvement in energy metabolism and the further implications
this may have for T2D risk is a disease mechanism demanding
more scrutiny.
The canonical Wnt signaling pathway is also implicated in
diverse neurological disorders such as autism, Alzheimer’s disease
and schizophrenia [33]. Consistent with a neurological function,
the TCF7L2 T2D-associated interval has been implicated in
schizophrenia risk [34]. Indeed, we observed behavioral pheno-
types in mice with altered Tcf7l2 levels [35]. As the historical co-
morbidity between T2D and schizophrenia is well documented,
this may point to a common disease etiology [36,37]. In light of
these observations, our identification of several brain enhancers,
and in particular a forebrain enhancer situated in the vicinity of
SNP rs7903146, may be of interest.
We did not observe robust allelic-specific enhancer activity for
SNP rs7903146. Although we cannot exclude potential effects at
other developmental stages, the use of a non-native promoter
element (Hsp68) or potential complex long-range interactions (i.e
enhancer-enhancer) that was not assessed by our assay may
explain these results. The previous localization of a pancreatic
enhancer using an in vivo BAC transgenic strategy supports these
conclusions [12]. Alternatively, as the allelic-specific properties at
this locus were uncovered through cell-based luciferase and open
chromatin assays [16,17], our results may primarily reflect a
limitation in assessing quantitative differences with qualitative
approaches. This carries broader implications for GWAS loci in
general as potential causal variants are likely to constitute a modest
effect on disease risk [38,39,40] and therefore may generate finer
regulatory defects that are difficult to assess in vivo.
Figure 1. Enhancer screen of evolutionary conserved sequences within TCF7L2 association interval. (A) The TCF7L2 gene is shown above
with the 92-kb T2D-associated internal highlighted in red. A red asterisk marks SNP rs7903146. Sequence conservation between human-opossum is
given (ECR genome browser, [43]). The 13 evolutionary conserved regions (ECRs) harboring conservation down to opossum are highlighted in grey
and numbered below. Regions exhibiting reproducible enhancer activity are marked in red. (B) Reproducible expression profiles from ECRs at
embryonic day 15.5 (E15.5) are shown. Expression can be seen in the stomach (ECR 1), neurons near the spine (ECR 3), limb bones and axial skeletion
(ECR 4), forebrain (dorsal view, ECR 5), walking pads (ECR 6), limb vasculature (ECR 8), brain vasculature (dorsal view, ECR 9), limbs and midbrain
(dorsal view, ECR 11), and phalangies (ECR 13). In ECRs 4, 6, 8, 11 and 13, both forelimb (left) and hindlimb (right) images are given. Reproducible
regulatory activities were not identified for ECRs 2, 7, 10 and 12.
doi:10.1371/journal.pone.0036501.g001
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embryonic developmental stage, E15.5. Despite this limitation,
our previous BAC results suggest that the regulatory landscape at
this locus is faithfully maintained into adulthood [12]. Another
potential concern is the use of evolutionary conserved sequences in
our in vivo assays. It has become common knowledge that a
number of cis-regulatory regions, including those involved in
embryonic development, lack evolutionary conservation across
distant species. Our in vivo scan is far from being exhaustive, and
we most likely missed other cis-regulatory elements embedded in
the ,50% of sequences within the T2D-associated region that we
did not test in this study. Nevertheless, our results conclusively
indicate that the T2D-associated interval contains at least nine
tissue-specific regulatory elements. Despite the strong concordance
with the endogenous TCF7L2 expression profile [12], we cannot
definitively rule out the possibility that some of these enhancers
could be involved in the regulation of neighboring genes such as
the upstream gene VTI1A. Genetic variation in a number of these
enhancers, common or rare in populations, may lead to alterations
in TCF7L2 or neighboring gene expression, leading to various
phenotypic consequences. To that end, the same genomic interval
has now also been associated with increased risk to schizophrenia
[34], colorectal cancer [41] and coronary artery disease [42].
Our results highlight the complex regulatory nature of the 92-kb
T2D-associated region of TCF7L2 and support the hypothesis that
sequence variation within distal cis-regulatory elements are
mediators of T2D susceptibility. The identification of several
enhancers that drive expression in diverse metabolic domains
further points to a possible disease etiology involving peripheral
metabolic tissues.
Figure 2. Functional analysis of SNP rs7903146. (A) The association interval within the TCF7L2 gene locus is highlighted in red above. A red
asterisk marks SNP rs7903146. Sequence conservation between human-opossum (ECR genome browser, [43]) is given for the entire association
interval while the sequence tested is highlighted in green. Within the tested region, sequence conservation between human-opossum is given below
(ECR genome browser). Positions of regions spanning SNP rs7903146 (5-C and 5-T) as well as a shorter sequence limited to the downstream ECR (5B)
are shown below. (B)-(D) Images of pancreas (attached to the stomach) (left) and brain (right, dorsal view) obtained from independent transgenic
lines (rows) are shown at E15.5 or E16.5 (ECR 5-C row 3 only). (B) and (C) Regions 5-C and 5-T exhibits inconsistent pancreatic staining while
maintaining reproducible forebrain expression. (B) Construct 5B harbors forebrain expression but no pancreatic staining.
doi:10.1371/journal.pone.0036501.g002
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Figure S1 Postnatal analyses of pancreatic expression.
Stable transgenic lines were stained for pancreatic beta-galacto-
sidase activity on postnatal days 0 (P0, top panel) and 6 (P6,
bottom panel). Pancreatic images for sequences spanning the
protective C allele at SNP rs7903146 (5-C) and risk T allele at
SNP rs7903146 (5-T) are shown.
(TIFF)
Table S1 Primer sequences for amplification of evolu-
tionary conserved regions within the TCF7L2 associa-
tion interval. The evolutionary conserved region (ECR) is
numbered in the first column. Subsequent columns give the
primer pair sequences (in 59 to 39 orientation) for each ECR.
(TIFF)
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